Society for Vascular Surgery

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024
Pulse, Interventional radiology, Health equity, SCAI, Society for Vascular Surgery, Pain, Peripheral artery disease, MD Anderson Cancer Center, Prevalence, Interventions, SIR, University, Heart, Health, Amputation, Society, Diabetes, Heated tobacco product, Smoker, Risk, Patient, Leg, Rest, Vascular disease, Society of Interventional Radiology, PAD, Walking, MBA, Association of Black Cardiologists, Doctor of Philosophy

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

Society for Vascular Surgery Foundation Launches September Vascular Health Step Challenge During PAD Awareness Month & Healthy Aging Month

Retrieved on: 
Friday, September 1, 2023
National Stroke Awareness Month, SVS, Plaque, Risk factor, Obesity, Society, Diabetes, Amputation, Stroke, PAD, Hypoesthesia, Leg, Research, Artery, Society for Vascular Surgery, Pain, Walking, Patient, Risk, Moyamoya disease, Ulcer, Death, Smoking, Conditional sentence, Birth control, Medical device

ROSEMONT, Ill., Sept. 1, 2023 /PRNewswire/ -- The Society for Vascular Surgery (SVS) Foundation today launched its second-annual September Vascular Health Step Challenge to raise awareness about vascular health and promote the benefits of walking for overall well-being, while also raising funds to benefit low-income vascular patients.

Key Points: 
  • ROSEMONT, Ill., Sept. 1, 2023 /PRNewswire/ -- The Society for Vascular Surgery (SVS) Foundation today launched its second-annual September Vascular Health Step Challenge to raise awareness about vascular health and promote the benefits of walking for overall well-being, while also raising funds to benefit low-income vascular patients.
  • The campaign coincides with Peripheral Arterial Disease (PAD) Awareness Month and Healthy Aging Month.
  • "The SVS Foundation invites the community to join our September Vascular Health Step Challenge and quite literally take steps toward better vascular health," says Dr. Joseph Mills, SVS President.
  • "The Vascular Health Step Challenge is not just about walking; it's about advocacy, awareness, and action," says Dr. Michael Dalsing, SVS Foundation Chair.

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)

Retrieved on: 
Thursday, April 27, 2023
General Health, Health, Clinical Trials, Medical Devices, Society, Freedom, Society for Vascular Surgery, Medical journal, AFX, ARC, Multimedia, Aortic aneurysm, The BMJ, Journal, Rupture, JVS, MD, Patient, Vascular disease, Randomized controlled trial, Use-centered design, Mortality, Patient safety organization, Medical imaging

Endologix LLC , a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the final five-year results of the LEOPARD Trial in the Journal of Vascular Surgery ( JVS1 ).

Key Points: 
  • Endologix LLC , a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the final five-year results of the LEOPARD Trial in the Journal of Vascular Surgery ( JVS1 ).
  • "We are proud to have conducted the first randomized controlled trial comparing commercially available endografts, and we remain committed to providing the highest quality clinical evidence that underpins our life-changing vascular therapies.
  • LEOPARD was a prospective, randomized, multi-center trial that enrolled 455 patients across 56 US Centers.
  • Five-Year Results of the LEOPARD Trial of Commercially Available Endografts.

New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE)

Retrieved on: 
Thursday, February 23, 2023
Beth Israel Deaconess Medical Center, Death, Safety, Journal of Vascular and Interventional Radiology, DVT, Society, Interventional radiology, PE, Embolism, Physician, JVIR, Recurrence, Inferior vena cava filter, PES, Risk, Health, Society of Interventional Radiology, Filter, Deep vein thrombosis, SIR, Journal, FDA, Radiology, Patient, Indiana University School of Medicine, Effectiveness, VTE, IVC, SVS, Society for Vascular Surgery, Coronary thrombosis, MS, FACS, Inferior vena cava, Pulmonary embolism, Birth control, Medical imaging, Nursing, MD, DRS

CHICAGO and FAIRFAX, Va., Feb. 23, 2023 /PRNewswire/ -- Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).

Key Points: 
  • PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers.
  • The study was conducted at 54 sites in the United States between Oct. 10, 2015, and March 31, 2019.
  • During that time, filters were implanted in 1,421 patients, of which 1,019 patients had an existing deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • Approximately half of the patients in the study had their filters removed within 3 months of placement without complication or recurrence of DVT or PE, according to study authors.

Renowned Vascular Surgeon Unveils Dark Side of the Medical Profession in Revealing New Memoir

Retrieved on: 
Tuesday, February 7, 2023
The New York Times, Society, Health, Cleveland, Playboy, Daily News, BPS Barbara Wilson Lifetime Achievement Award, Barnes & Noble, Society for Vascular Surgery, Patient, Disclosure, European Society of Gynaecological Oncology, Bell, Sale, New York, New York, Publishing, Cleveland Clinic, NYU, Multimedia, Environment, Medicine, MD, Hospital, Dentistry, Chicago Tribune, Los Angeles Times, Amazon

NEW YORK, Feb. 7, 2023 /PRNewswire/ -- From celebrated vascular surgeon and veteran medical maverick Dr. Frank J. Veith comes a captivating memoir and exposé of the medical establishment that unveils an often clubby industry that many believe needs serious reform.

Key Points: 
  • NEW YORK, Feb. 7, 2023 /PRNewswire/ -- From celebrated vascular surgeon and veteran medical maverick Dr. Frank J. Veith comes a captivating memoir and exposé of the medical establishment that unveils an often clubby industry that many believe needs serious reform.
  • Part captivating memoir, part disclosure of a self-serving system, The Medical Jungle recounts Dr. Veith's tireless efforts to improve medical care for patients.
  • The Medical Jungle will inspire anyone who faces adversity at any level to stand up and be radical, even when it is unpopular.
  • A starred review from Blue Ink Review calls The Medical Jungle "a fascinating chronicle of the complex inner workings of the 'medical jungle,'" while Kirkus calls the book "an engaging and evocative medical memoir."

ISET celebrates 35th anniversary meeting with nearly 1,000 registrants, record-breaking number of research submissions, sold out Exhibit Hall

Retrieved on: 
Thursday, January 19, 2023
Convention, PE, National Primate Research Exhibition Hall, University of Pennsylvania, SVM, Baptist Health, SIR, MVP, Florida International University, University, Record, Interventional radiology, Division, Movement, 2021 Essex County Council election, Society for Vascular Surgery, Society, FIU Herbert Wertheim College of Medicine, SVS, Centre for the Advancement of Sustainable Medical Innovation, FACC, Faculty, HMP, Society of Interventional Radiology, Town hall, ISET, Organization, Partnership, CME, Radiology, Society for Vascular Medicine, Degenerative disease, Research, International Symposium on Endovascular Therapy, Amputation, CLI, CNE, PAD, Health, Pharmaceutical industry, Medicine, Dentistry, MD

MALVERN, Pa., Jan. 19, 2023 /PRNewswire-PRWeb/ -- For its 35th annual gathering, HMP Global's International Symposium on Endovascular Therapy (ISET) received a record-breaking amount of research submissions, welcomed nearly 1,000 registrants from around the globe, and hosted more than 40 companies in its sold-out Exhibit Hall, solidifying its position as the premier arena for pioneering and practical endovascular education.

Key Points: 
  • "From the group that pioneered live case education, ISET has grown tremendously since the first meeting 35 years ago," Katzen said.
  • "Now as the leading meeting in endovascular therapy, ISET brings together a multidisciplinary faculty and audience to discuss groundbreaking techniques, implement change, and improve patient care.
  • All abstracts underwent blind peer review for quality of research, educational or scientific content, logical presentation, and impact on healthcare.
  • Cutting-edge research e-posters were displayed on multimedia screens in the poster area of the Exhibit Hall at ISET, and late-breaking data was presented at the first major endovascular meeting in 2023.

CardioVascular Coalition Sounds Alarm on Clinical Labor Cuts Causing More Amputations

Retrieved on: 
Wednesday, December 7, 2022
Society, Society for Vascular Surgery, CMS, Leg, Surgeon, Centers for Medicare & Medicaid Services, Native Americans, Peripheral artery disease, Hardship, FACS, Chronic pain, Patient, African Americans, Disability, Jacqueline Oble, Diabetes, Kidney disease, Quality of life, Member and Employee Training and Oversight On Congress Act, Amputation, PAD, RVT, The Dartmouth Institute for Health Policy and Clinical Practice, Congress, Depression, Medicare, Risk, Pharmaceutical industry, Health insurance, Hospital

WASHINGTON, Dec. 7, 2022 /PRNewswire-PRWeb/ -- Unless Congress Acts, Ongoing Clinical Labor Cuts Will Worsen Amputation Epidemic

Key Points: 
  • America's amputation epidemic will get worse if Congress fails to stop the ongoing clinical labor cuts outlined in the 2023 Medicare Physician Fee Schedule.
  • As a health care provider, I find this alarming, and I'm calling on Congress to prevent and reverse these cuts.
  • I'm calling on Congress to use its power to stop ongoing clinical labor cuts in the 2023 Medicare Physician Fee Schedule final rule.
  • It is crucial to giving patients the appropriate medical care they need to prevent needless amputations, particularly in underserved areas.

Avianne P. Bunnell, MD, RPVI is recognized by Continental Who's Who

Retrieved on: 
Monday, November 28, 2022
UCF, Basic life support, Medical University of South Carolina, University, Advanced trauma life support, Society for Vascular Surgery, Multimedia, Medical school, Varicose veins, Society, Central Florida, Laser, Vein, Aneurysm, College of Medicine, Advanced cardiac life support, The Vein, RPVI, SPRING, Stroke, Continental, Dentistry, MD

SPRING HILL, Fla., Nov. 28, 2022 /PRNewswire/ -- Avianne P. Bunnell, MD, RPVI, is being recognized by Continental Who's Who as an Outstanding Medical Professional in acknowledgment of her outstanding work at The Vein and Vascular Institute.

Key Points: 
  • SPRING HILL, Fla., Nov. 28, 2022 /PRNewswire/ -- Avianne P. Bunnell, MD, RPVI, is being recognized by Continental Who's Who as an Outstanding Medical Professional in acknowledgment of her outstanding work at The Vein and Vascular Institute.
  • Dr. Avianne Bunnell is a board-certified in vascular surgery and is highly skilled in the most cutting-edge and advanced technologies in vascular care.
  • With eight years of experience, Dr. Bunnell is a vascular surgeon passionate about providing compassionate and unsurpassed clinical and surgical care.
  • Dr. Bunnell is also certified Registered Physician in Vascular Interpretation (RPVI), meaning she is certified to read and interpret all vascular ultrasounds.

Lucy Therapeutics Expands Leadership Team with Appointment of Julia Gaebler, Ph.D., as Chief Business Officer

Retrieved on: 
Tuesday, November 15, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Journal, Graduate school, Johns Hopkins University, Partnership, Infection, Degenerative disease, Therapy, Diagnosis, Lucy, Patient, Mitochondrion, Hoffmann-La Roche, Multimedia, Paul H. Nitze School of Advanced International Studies, Economics, Frederick S. Pardee RAND Graduate School, Health policy, Biomarker, CNS, Research, Doctor of Philosophy, Metabolism, Genetics, University, Disease, M.A, Harvard University, Growth, Central nervous system, Multiple sclerosis, Rett syndrome, Drug discovery, Public health, Gaebler Children's Center, University of California, The Journal of Pediatrics, Society for Vascular Surgery, Health, Medtech, Rett, Pharmaceutical industry, Nature, Biogen, Pediatrics

Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.

Key Points: 
  • Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.
  • Dr. Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, across biopharma, consulting, and academia.
  • View the full release here: https://www.businesswire.com/news/home/20221115005644/en/
    Dr. Gaebler will direct Lucy Therapeutics fundraising, growth and partnership activities for its promising proprietary preclinical compounds in Parkinsons disease, Rett syndrome, and other diseases of mitochondrial dysfunction.
  • Prior to joining Lucy Therapeutics, Dr. Gaebler was vice president of commercial strategy and portfolio planning at Milestone Pharmaceuticals and partner at Health Advances, a life-sciences strategy consulting firm.